SCHEMBL274378

SCHEMBL274378

O=Cc1cc(F)ccc1OC1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.42
PDE4D Q08499 7/20 0.41
PDE4B Q07343 6/20 0.41
PDE4A P27815 5/20 0.41
PDE4C Q08493 5/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
EPHX2 P34913 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PTGDR Q13258 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL275026 0.98 POLB (0.45) POLBPTGDR2PDE4DPDE4BPDE4A
SCHEMBL275208 0.85 ALDH1A1 (0.39) POLBPDE4BALDH1A1MAPT
SCHEMBL275678 0.85 SYK (0.45) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL276177 0.81 POLB (0.44) POLBPDE4DPDE4BPDE4APDE4C
SCHEMBL275626 0.81 POLB (0.44) POLBPTGDR2PDE4DPDE4BPDE4A
SCHEMBL11779563 0.80 SRC (0.49) POLBPTGDR2ALDH1A1
SCHEMBL17352923 0.80 PDE4D (0.46) PDE4DPDE4BPDE4APDE4C
SCHEMBL31006004 0.80 PDE4D (0.46) PDE4DPDE4BPDE4APDE4C
SCHEMBL7662729 0.79 POLB (0.45) POLBPTGDR2PDE4DPDE4BPDE4A
SCHEMBL5302703 0.78 ALDH1A1 (0.50) POLBPTGDR2PDE4DPDE4BPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT POLB 2672/4885PTGDR2 996/4885PDE4D 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.